Anti-DFS70 antibodies have been recently included in a new testing algorithm for patients with suspicion of connective tissue diseases (CTDs). This algorithm enables to assess the probability of having a CTD in patients with a positive antinuclear antibodies (ANA) result. The aim of the study was to analyze the inter-method agreement between three different HEp-2 cell substrates for anti-DFS70 detection, focusing on two novel IIF methods that assess the presence of monospecific anti-DFS70 antibodies.
In 1890, antibody therapy burst out into the world for the first time. Nobel Prize winner Emil von Behring and colleagues showed that transfusion of serum from diphtheria toxin–injected rabbits into naıve
rabbits resulted in immunity.
Microbiome, autoimmunity, allergy, and helminth infection: The importance of the pregnancy period
This study received funding from the Swedish Foundation for Strategic Research, the Swedish Research Council, the Swedish COMBINE public-private research programme, the Swedish Cancer
Society, the Lions Cancer Research Foundation in Uppsala, the Swedish Rheumatism Association, the EU-IMI BT Cure project, King Gustaf V's 80 year Foundation, SFO Epidemiology at Karolinska Institutet, and Stockholm County Council.